FeesSafety
Pluang+

Berkshire Hathaway shares often drop sharply but recover strongly, says Warren Buffett.

Market News
19 Nov 2026, 03:05 WIB
The Motley Fool
View Source
Neutral
Berkshire Hathaway shares often drop sharply but recover strongly, says Warren Buffett.

Warren Buffett highlights that Berkshire Hathaway's stock has experienced significant drops of around 50% multiple times over 60 years but always recovered and reached new highs. These declines vary in length, from weeks to years, reflecting typical market pullbacks. Buffett advises investors to expect downturns, hold stocks long-term, and view market dips as buying opportunities. This perspective underscores the importance of patience and resilience in stock investing.

Warren Buffett's view on Berkshire Hathaway stock is presented here with Financials sector data from Pluang as of Nov 19, 2026 06:11 WIB. For readers following Financials, here is Pluang's market snapshot: out of 142 priced US Financials stocks, 26 rose and 115 fell today. Notable movers include BTBT at USD 0.63 with a 1-day change of -4.79% and a Pluang order activity of 31% Sell / 69% Buy, Western Union Co (WU) at USD 6.16 down 4.64% with 100% Sell orders, and Moody's Corporation (MCO) at USD 483.00 down 4.60% with 96% Sell orders. The most notable figure is the heavy sell activity on WU at 100%.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App